NR2F1 and breast carcinoma: NR2F1-AS1 has been shown to facilitate malignant tumor development in non-small cell lung cancer (Zhang C. et al., 2020), breast cancer (Zhang Q. et al., 2020), bone cancer (Li et al., 2019), thyroid cancer (Guo et al., 2019), and endometrial cancer (Wang et al., 2019), as well as tumor cell EMT in liver cancer (Ji et al., 2021) and esophageal squamous cell cancer (Wang et al., 2019).